Sermorelin and tesamorelin get compared constantly — they're both growth hormone-releasing hormone (GHRH) analogs, they both show up on longevity-clinic menus, and peptide vendor sites sell vials of both. The comparison most of those sites offer is a spec-sheet shootout. The comparison that actually matters is regulatory: these two molecules live in completely different legal worlds, and that difference determines what you can legitimately get, from whom, and for what.
The short version: tesamorelin is an FDA-approved prescription drug (Egrifta®) for one specific condition — excess abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin is not currently an FDA-approved product; it's prepared per-patient by licensed compounding pharmacies and prescribed when a clinician decides it's clinically appropriate. Neither is growth hormone, neither is an HGH replacement, and the vials sold online under either name are a third thing entirely — research-grade material outside the pharmacy system.
First, what they have in common
Your body regulates growth hormone through a signaling chain: the hypothalamus releases GHRH, which prompts the pituitary gland to produce and release growth hormone in pulses. Both sermorelin and tesamorelin are synthetic analogs of that GHRH signal — they work upstream, acting on the pituitary to encourage the body's own production pathways rather than supplying growth hormone directly.
Structurally, sermorelin is an analog of the first 29 amino acids of GHRH — the fragment responsible for the signal. Tesamorelin is a full-length GHRH analog with a chemical modification that makes it more resistant to breakdown in the body. Same family, same upstream mechanism, different molecules.
That's where the similarity ends, because what happened to each molecule after it was synthesized could not be more different.
Tesamorelin: an approved drug, for a specific condition
Tesamorelin was developed by Theratechnologies and approved by the FDA in November 2010 as Egrifta® — the first approved treatment for lipodystrophy, specifically the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. A newer weekly-reconstitution formulation, EGRIFTA WR™, was approved in 2025. It's a specialty prescription medication, prescribed within that clinical context, dispensed through the regulated pharmacy channel like any brand drug.
Two things follow from that, and both get blurred online:
- The approval is for that indication. Tesamorelin has not been approved for anti-aging, wellness, body composition, or "optimization" in the general population. An FDA approval is not a general-purpose endorsement of a molecule — it belongs to a specific product, for a specific use, in a specific population.
- The approved product is Egrifta®. A vial labeled "tesamorelin" from a peptide vendor is not Egrifta — it's research-grade material with no licensed pharmacy, no prescriber, and no verified identity, purity, or sterility behind it. The molecule's name does not carry the drug's credentials.
Sermorelin: a compounded medication, prescribed case by case
Sermorelin has the more winding history. It was an FDA-approved product — Geref®, used in diagnosing and treating growth hormone deficiency in children — until its manufacturer discontinued it in 2008. The FDA later formally determined, in a 2013 Federal Register notice, that Geref was not withdrawn for safety or effectiveness reasons — it was a business decision. That determination matters: it's part of why sermorelin, unlike the headline research peptides, has a lawful pathway through pharmacy compounding today.
The sermorelin prescribed now is compounded per-patient by state-licensed US pharmacies against a clinician's prescription, and it is not FDA-approved — a factual status worth understanding rather than glossing over. It means today's sermorelin hasn't gone through the approval process for a labeled indication, and it's exactly why a legitimate program gates everything behind a US-licensed clinician who reviews your health history and prescribes only when clinically appropriate. The full picture is in What is sermorelin? A plain-English guide.
The comparison that's actually useful
| Sermorelin | Tesamorelin | |
|---|---|---|
| What it is | Analog of the first 29 amino acids of GHRH | Full-length GHRH analog, stabilized against breakdown |
| Regulatory status | Compounded per-patient by licensed US pharmacies | FDA-approved drug: Egrifta® |
| Approved indication | None currently (previously approved as Geref®; discontinued 2008 for business reasons) | Excess abdominal fat in adults with HIV-associated lipodystrophy |
| How it's legitimately obtained | Telehealth or in-person prescription from a licensed clinician, prepared by a licensed compounding pharmacy | Specialty prescription within its approved clinical context |
| What the online vials are | Not the compounded medication — research-grade material, no pharmacy involved | Not Egrifta® — research-grade material, no pharmacy involved |
Notice what this table doesn't have: an efficacy row. That's deliberate.
So which one is "better"?
This is the question the comparison articles promise to answer, and the honest response is that it's the wrong question. There is no legitimate head-to-head to cite, and the two molecules aren't competing options on a menu:
- Tesamorelin is prescribed for a specific diagnosed condition, in a specific population. If you don't have that condition, tesamorelin isn't "the stronger option you're missing out on" — it's a specialty drug for someone else's diagnosis.
- Sermorelin is prescribed when a licensed clinician reviews an individual patient's health history and judges it clinically appropriate. That's a clinical determination, not a ranking.
A site that ranks them "head to head" for wellness purposes is comparing two things neither molecule's actual regulatory status supports — usually to sell you a vial of one of them.
About those vendor vials
Search either molecule and much of what you'll find is "research use only" vials. Whatever the name on the label, the profile is the same: no prescription, no licensed pharmacy, no FDA-registered sourcing, no verified contents. The label exists to shift legal risk to the buyer. Our guides to peptide regulation and what's legal state by state cover how to tell a lawful pathway from a storefront.
Where Pallas stands
Pallas offers clinician-prescribed compounded sermorelin — the lawful compounding pathway, with a US-licensed clinician making the prescribing decision and a state-licensed US pharmacy preparing each prescription from FDA-registered ingredient sourcing. The program is $89 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. One all-in price: clinician care, ongoing check-ins, care-team messaging, and your medication when prescribed. Details at the sermorelin program page.
Pallas does not offer tesamorelin. Egrifta® is a specialty medication prescribed within its approved clinical context, and anything sold outside that context isn't a medication we'd dispense — no matter the demand.
See if sermorelin is appropriate for you
A US-licensed clinician reviews your health history and determines whether sermorelin is clinically appropriate — and tells you honestly if it isn't.
Start your intake →References
Regulatory facts above are drawn from FDA and Federal Register primary sources; status reflects the rules as of this writing.
- U.S. Food and Drug Administration. EGRIFTA® (tesamorelin for injection) prescribing information.
- Federal Register. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. March 4, 2013.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
Frequently asked questions
Frequently asked questions
No. They're related — both are synthetic analogs of growth hormone-releasing hormone (GHRH), working upstream on the pituitary gland to encourage the body's own growth hormone release — but they're different molecules with completely different regulatory statuses. Tesamorelin is an FDA-approved drug (Egrifta®) for one specific condition; sermorelin is prepared per-patient by licensed compounding pharmacies and prescribed when a clinician decides it's clinically appropriate.
Yes — as Egrifta®, approved in 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, with a newer weekly-reconstitution formulation approved in 2025. The approval is specific to that indication and that product: tesamorelin is not approved for anti-aging, wellness, or body composition in the general population, and a vial labeled "tesamorelin" from a peptide vendor is research-grade material, not Egrifta®.
That's the question the comparison sites promise to answer, and the honest response is that it's the wrong question — there is no legitimate head-to-head to cite, and the two aren't competing options on a menu. Tesamorelin is prescribed for a specific diagnosed condition in a specific population; sermorelin is prescribed when a licensed clinician reviews an individual's health history and judges it clinically appropriate. A site ranking them for wellness purposes is usually selling a vial of one of them.
Not through Pallas — we don't offer it. Egrifta® is a specialty medication prescribed within its approved clinical context (HIV-associated lipodystrophy). Websites offering "tesamorelin" outside that context are selling research-use-only vials with no licensed pharmacy or prescriber involved — a different product wearing the same name.
No. HGH therapy supplies growth hormone directly; sermorelin is the releasing signal, working upstream by encouraging the pituitary gland's own production. Sermorelin is not growth hormone, not an HGH replacement, and not a "milder" or "natural" version of it — they're different medications with different clinical reasoning behind them.
At Pallas, the sermorelin program is $89 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. One all-in price covers your US-licensed clinician, ongoing check-ins, care-team messaging, and your medication when prescribed, with free shipping from a US-licensed pharmacy. If a clinician decides treatment isn't right for you, you're refunded in full.